Annual CFO
-$12.38 M
+$9.97 M+44.60%
31 December 2023
Summary:
Entero Therapeutics annual cash flow from operations is currently -$12.38 million, with the most recent change of +$9.97 million (+44.60%) on 31 December 2023. During the last 3 years, it has risen by +$19.91 million (+61.66%). ENTO annual CFO is now -196.81% below its all-time high of -$4.17 million, reached on 01 December 2015.ENTO Cash From Operations Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly CFO
-$1.85 M
+$1.60 M+46.43%
01 September 2024
Summary:
Entero Therapeutics quarterly cash flow from operations is currently -$1.85 million, with the most recent change of +$1.60 million (+46.43%) on 01 September 2024. Over the past year, it has increased by +$1.59 million (+46.26%). ENTO quarterly CFO is now -190.42% below its all-time high of -$636.50 thousand, reached on 01 March 2016.ENTO Quarterly CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM CFO
-$12.49 M
+$1.48 M+10.61%
01 September 2024
Summary:
Entero Therapeutics TTM cash flow from operations is currently -$12.49 million, with the most recent change of +$1.48 million (+10.61%) on 01 September 2024. Over the past year, it has dropped by -$107.90 thousand (-0.87%). ENTO TTM CFO is now -1117.06% below its all-time high of -$1.03 million, reached on 01 March 2015.ENTO TTM CFO Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
ENTO Cash From Operations Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | - | +46.3% | -0.9% |
| 3 y3 years | +61.7% | +68.5% | +61.3% |
| 5 y5 years | +11.8% | +42.7% | +11.0% |
ENTO Cash From Operations High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | at high | +61.7% | at high | +76.6% | -0.9% | +64.5% |
| 5 y | 5 years | -10.3% | +61.7% | -43.1% | +88.3% | -45.9% | +64.5% |
| alltime | all time | -196.8% | +61.7% | -190.4% | +88.3% | -1117.1% | +64.5% |
Entero Therapeutics Cash From Operations History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$1.85 M(-46.4%) | -$12.49 M(-10.6%) |
| June 2024 | - | -$3.45 M(-7.9%) | -$13.97 M(+5.2%) |
| Mar 2024 | - | -$3.75 M(+8.9%) | -$13.28 M(+7.3%) |
| Dec 2023 | -$12.38 M(-44.6%) | -$3.44 M(+3.2%) | -$12.38 M(-14.8%) |
| Sept 2023 | - | -$3.33 M(+20.6%) | -$14.53 M(-6.0%) |
| June 2023 | - | -$2.76 M(-2.9%) | -$15.45 M(-10.6%) |
| Mar 2023 | - | -$2.85 M(-49.1%) | -$17.28 M(-22.7%) |
| Dec 2022 | -$22.34 M(-30.8%) | - | - |
| Dec 2022 | - | -$5.59 M(+31.5%) | -$22.34 M(-1.2%) |
| Sept 2022 | - | -$4.25 M(-7.2%) | -$22.61 M(-33.7%) |
| June 2022 | - | -$4.59 M(-42.0%) | -$34.09 M(-3.0%) |
| Mar 2022 | - | -$7.91 M(+35.0%) | -$35.13 M(+8.8%) |
| Dec 2021 | -$32.29 M(+187.7%) | -$5.86 M(-62.7%) | -$32.29 M(-0.1%) |
| Sept 2021 | - | -$15.73 M(+179.7%) | -$32.32 M(+67.6%) |
| June 2021 | - | -$5.62 M(+10.8%) | -$19.28 M(+28.5%) |
| Mar 2021 | - | -$5.07 M(-13.9%) | -$15.00 M(+33.7%) |
| Dec 2020 | -$11.22 M(-20.0%) | -$5.89 M(+118.4%) | -$11.22 M(+31.1%) |
| Sept 2020 | - | -$2.70 M(+100.7%) | -$8.56 M(-14.5%) |
| June 2020 | - | -$1.34 M(+4.0%) | -$10.01 M(-21.1%) |
| Mar 2020 | - | -$1.29 M(-60.0%) | -$12.70 M(-9.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2019 | -$14.03 M(+29.1%) | -$3.23 M(-22.3%) | -$14.03 M(-0.8%) |
| Sept 2019 | - | -$4.15 M(+3.2%) | -$14.15 M(+11.7%) |
| June 2019 | - | -$4.03 M(+53.2%) | -$12.66 M(+12.2%) |
| Mar 2019 | - | -$2.63 M(-21.3%) | -$11.28 M(+3.8%) |
| Dec 2018 | -$10.87 M(+51.3%) | -$3.34 M(+25.3%) | -$10.87 M(+8.7%) |
| Sept 2018 | - | -$2.67 M(+0.7%) | -$10.00 M(+15.9%) |
| June 2018 | - | -$2.65 M(+19.6%) | -$8.62 M(+4.8%) |
| Mar 2018 | - | -$2.21 M(-10.3%) | -$8.23 M(+14.6%) |
| Dec 2017 | -$7.18 M(+58.4%) | -$2.47 M(+90.9%) | -$7.18 M(+6.7%) |
| Sept 2017 | - | -$1.29 M(-42.7%) | -$6.73 M(+1.0%) |
| June 2017 | - | -$2.26 M(+93.7%) | -$6.67 M(+31.6%) |
| Mar 2017 | - | -$1.17 M(-42.2%) | -$5.06 M(+11.7%) |
| Dec 2016 | -$4.53 M(+8.7%) | -$2.02 M(+64.5%) | -$4.53 M(+40.2%) |
| Sept 2016 | - | -$1.23 M(+87.1%) | -$3.24 M(-13.9%) |
| June 2016 | - | -$655.40 K(+3.0%) | -$3.76 M(-0.6%) |
| Mar 2016 | - | -$636.50 K(-11.3%) | -$3.78 M(-9.3%) |
| Dec 2015 | -$4.17 M | -$717.20 K(-59.0%) | -$4.17 M(+20.8%) |
| Sept 2015 | - | -$1.75 M(+157.0%) | -$3.45 M(+102.4%) |
| June 2015 | - | -$679.90 K(-33.7%) | -$1.71 M(+66.3%) |
| Mar 2015 | - | -$1.03 M | -$1.03 M |
FAQ
- What is Entero Therapeutics annual cash flow from operations?
- What is the all time high annual CFO for Entero Therapeutics?
- What is Entero Therapeutics quarterly cash flow from operations?
- What is the all time high quarterly CFO for Entero Therapeutics?
- What is Entero Therapeutics quarterly CFO year-on-year change?
- What is Entero Therapeutics TTM cash flow from operations?
- What is the all time high TTM CFO for Entero Therapeutics?
- What is Entero Therapeutics TTM CFO year-on-year change?
What is Entero Therapeutics annual cash flow from operations?
The current annual CFO of ENTO is -$12.38 M
What is the all time high annual CFO for Entero Therapeutics?
Entero Therapeutics all-time high annual cash flow from operations is -$4.17 M
What is Entero Therapeutics quarterly cash flow from operations?
The current quarterly CFO of ENTO is -$1.85 M
What is the all time high quarterly CFO for Entero Therapeutics?
Entero Therapeutics all-time high quarterly cash flow from operations is -$636.50 K
What is Entero Therapeutics quarterly CFO year-on-year change?
Over the past year, ENTO quarterly cash flow from operations has changed by +$1.59 M (+46.26%)
What is Entero Therapeutics TTM cash flow from operations?
The current TTM CFO of ENTO is -$12.49 M
What is the all time high TTM CFO for Entero Therapeutics?
Entero Therapeutics all-time high TTM cash flow from operations is -$1.03 M
What is Entero Therapeutics TTM CFO year-on-year change?
Over the past year, ENTO TTM cash flow from operations has changed by -$107.90 K (-0.87%)